Antibody-drug conjugates (ADCs) represent a cutting-edge advancement in cancer therapy. These unique biopharmaceuticals act as "smart bombs," combining monoclonal antibodies specifically targeting cancer cells with potent cytotoxic drugs delivered directly to the tumor site. This precise targeting reduces collateral damage to healthy cells, minimizing adverse effects. Given the growing adoption of ADCs in clinical oncology, predicting their efficacy has become a critical challenge. Factors such as tumor heterogeneity, antigen expression, and individual patient differences underscore the need for precise biomarkers and advanced tools to determine patient suitability. The integration of immunohistochemistry (IHC) and next-generation sequencing (NGS) has emerged as a powerful approach to refining this prediction process. This blog explores the challenges of predicting ADC efficacy, the roles of IHC and NGS, and how these technologies are shaping the future of ADC-based therapy.
